logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer

< Back

Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer

Drugs

Cancer and Palliative Care

October 2021


Sacituzumab govitecan is in clinical development for the treatment of adult patients with hormone receptor positive and human epidermal growth factor 2 negative (HR+/HER2-) metastatic breast cancer, whose disease has progressed despite treatment with at least two prior rounds of chemotherapy. Survival outcomes for patients with metastatic breast cancer are poor and current chemotherapy options are associated with adverse side effects so there is a need for additional therapies for these patients.
Sacituzumab govitecan belongs to a class of medicinal products called antibody drug conjugates (ADCs) which are developed by attaching (conjugating) a specific protein, called a monoclonal antibody, to an anti-cancer drug. The monoclonal antibody component of savicituzumab govitecan specifically targets and attaches to a protein, TROP-2, which is found on the surface of cancer cells allowing the entry of the sacituzumab govitecan into the cancer cell. Once inside the cell the anti-cancer drug SN-38 is released resulting in DNA damage that causes death of the cancerous cells. Sacituzumab govitecan is administered by intravenous infusion (IV) and if licensed will offer an additional treatment option for patients with HR+/HER2- metastatic breast cancer whose disease has progressed despite treatment with at least two prior rounds of chemotherapy.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts